GSK plc - 07 Nov 2022 Form 3 Insider Report for Spero Therapeutics, Inc. (SPRO)

Reporting relationship: 10%+ Owner
Issuer ticker: SPRO
Reported as of: 07 Nov 2022
Net transaction value: $0
SEC form: 3
Accepted by SEC: 14 Nov 2022, 16:05:12 UTC
Prior SEC filing: 20 Sep 2022
Next SEC filing: 30 Jan 2023
Source filing: View source filing
Reporting owner signature: Victoria Whyte, Authorized Signatory, GSK plc

Key filing fact

GSK plc filed Form 3 for Spero Therapeutics, Inc. (SPRO) on 14 Nov 2022.

Key facts

This page summarizes GSK plc's Form 3 filing for Spero Therapeutics, Inc. (SPRO).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Nov 2022, 16:05.

Change

Previous filing in this sequence was filed on 20 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,190,606
Date: 07 Nov 2022
Ownership: See footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares reported herein are held of record by GSK Equity Investments, Limited, and Glaxo Group Limited, each of which is an indirect, wholly-owned subsidiary of GSK plc (the "Reporting Person").